Article

Nuclear karyopherin α2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity

West German Study Group, Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.
International Journal of Cancer (Impact Factor: 5.01). 09/2008; 123(6):1433-8. DOI: 10.1002/ijc.23628
Source: PubMed

ABSTRACT Intensive lymph node involvement indicates poor prognosis in breast cancer patients. The significance of other molecular prognostic factors in this subgroup is unclear. Karyopherin alpha2 (KPNA2) has been reported as an important factor of tumorgenesis and progression of breast cancer. The aim of present study was to evaluate the impact of KPNA2 expression on prognosis of patients with high risk breast cancer (HRBC) and response intensive chemotherapy within the randomized WSG-AM-01 trial. KPNA2 nuclear expression (>10% vs. <10% of nuclei) was measured by immunohistochemistry on tissue arrays of 191 patients randomized to tandem high dose vs. conventional dose-dense chemotherapy in HRBC with >9 positive lymph nodes and correlated with clinical outcome (median follow-up of 63.3 months) by Kaplan-Meier and multivariate Cox hazard model analysis, including, molecular subtypes determined by k-clustering (k = 5). KPNA2 overexpression (n = 74, 39%) significantly correlated with shorter event-free and overall survival (OS) in both therapy arms by univariate analysis. Multivariate analysis showed that the overexpression of KPNA2 was an independent prognostic factor of decreased OS HR = 1.86 [95% CI: 1.07-3.23, p = 0.03]. This predictive value was independent of basal-like/Her-2/neu subtypes, significantly associated with KPNA2 and was addressed particularly to G2 tumors. Our data suggest the use of KPNA2 nuclear expression as novel prognostic marker in node-positive patients, especially in determination of G2 tumors in 2 subgroups of different prognosis. KPNA2 expression may be also considered as a marker for global chemoresistance, which can not be overcome by conventional dose-modification of chemotherapy in advanced breast cancer.

Download full-text

Full-text

Available from: Andreas Gaumann, Jul 29, 2015
0 Followers
 · 
109 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: During the past decade, a new dynamic perspective of vitamin D receptor (VDR) and retinoid X receptor (RXR) functions has emerged. The ability to monitor receptor movement in living cells by fluorescent techniques in real time has led to the realization that VDR, RXR, and most other nuclear receptors (NRs) and transcription factors constantly shuttle between the cytoplasm and the nucleus as well as between subnuclear compartments, and revealed the transient nature of receptor–DNA interactions. In this review, the significance of receptor trafficking is first highlighted, along with diseases associated with abnormal receptor localization. The significance of spatial and temporal control of transcription for the regulation of cell growth and differentiation is emphasized. Next, our current knowledge of the nuclear import and export machinery is summarized. Regulation of NR transport is discussed at the level of the receptor (nuclear localization sequence and nuclear export sequence modifications), at the level of import and export receptor expression, and at the level of signal-dependent changes in nuclear pore complex conformation. An understanding of how nuclear architecture and intranuclear NR mobility contribute to gene regulation concludes the review of the general aspects of NR trafficking. Then, information specific for VDR and RXR import, export, and intranuclear trafficking is presented in detail. Conclusions emphasize that understanding the spatial and temporal aspects of VDR functions is important, and express hope that rapid initial progress in this area will not be halted by economic and ideological pressure.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer is a highly aggressive malignancy and one of the leading causes of cancer deaths, mainly due to the lack of methods for early diagnosis and the lack of effective therapies. Recent CGH microarray studies have revealed several regions that are recurrently amplified in pancreatic cancer; these are thus likely to contain genes that contribute to cancer pathogenesis and thereby could serve as novel diagnostic and therapeutic targets. Here, we performed a detailed characterization of the 7q21-q22 amplicon in pancreatic cancer to identify putative amplification target genes. Fluorescence in situ hybridization analyses in 16 pancreatic cancer cell lines and 29 primary pancreatic tumors revealed an increased copy number in approximately 25% of cases in both sample groups, and the cell line data also allowed us to identify a 0.77 Mb amplicon core region containing ten transcripts. Gene expression analyses by qRT-PCR highlighted the ARPC1A gene as having the statistically most significant correlation between amplification and elevated expression (P = 0.004). Silencing of ARPC1A by RNA interference in AsPC-1 cells having high level amplification and expression resulted in a slight decrease in cell proliferation, but a massive reduction in cell migration and invasion. ARPC1A codes for the p41 subunit of the Arp2/3 protein complex, which is a key player in actin polymerization and thus regulates cell mobility. Taken together, our data implicate ARPC1A as a novel target for the 7q21-q22 amplification and a regulator of cell migration and invasion in pancreatic cancer, thus making it an interesting target for antimetastasis therapy.
    Genes Chromosomes and Cancer 04/2009; 48(4):330-9. DOI:10.1002/gcc.20643 · 3.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In an attempt to understand the molecular characterization for the early adenocarcinoma of the uterine cervix, an analysis of gene expression profiles obtained from early adenocarcinoma of the uterine cervix was performed to find those genes most aberrantly expressed. Total RNA was prepared from 32 samples of early adenocarcinoma of the uterine cervix and 32 paired normal cervix tissues, and hybridized to cancer-associated oligonucleotide microarrays with probe sets complementary to about 1,426 transcripts. Supervised analysis of gene expression data identified 13 genes that exhibited >2-fold upregulation and 27 genes >2-fold downregulation, respectively, in early adenocarcinoma of the uterine cervix compared to normal cervix. Unsupervised hierarchical clustering of the expression data readily distinguished early adenocarcinoma of the uterine cervix from normal cervix. Two genes (karyopherin alpha 2 and proliferating cell nuclear antigen) were selected randomly for real-time reverse transcription polymerase chain reaction analysis. Both genes were expressed significantly higher in early adenocarcinoma of the uterine cervix than in normal cervix, with p = 0.0003 and <0.0001, respectively. These results were compatible with the microarray data. This study has revealed several genes that may be highly attractive candidate molecular markers/targets for early adenocarcinoma of the uterine cervix.
    Archives of Gynecology 05/2010; 283(4):861-9. DOI:10.1007/s00404-010-1511-4 · 1.28 Impact Factor
Show more